Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


Articles published in Oncologist

Retrieve available abstracts of 45 articles:
HTML format
Text format



Single Articles


    February 2017
  1. ROTH JA, Goulart BH, Ravelo A, Kolkey H, et al
    Survival Gains from First-Line Systemic Therapy in Metastatic Non-Small Cell Lung Cancer in the U.S., 1990-2015: Progress and Opportunities.
    Oncologist. 2017 Feb 27. pii: theoncologist.2016-0253.
    PubMed     Text format     Abstract available


    January 2017
  2. DONG ZY, Zhai HR, Hou QY, Su J, et al
    Mixed Responses to Systemic Therapy Revealed Potential Genetic Heterogeneity and Poor Survival in Patients with Non-Small Cell Lung Cancer.
    Oncologist. 2017;22:61-69.
    PubMed     Text format     Abstract available


    November 2016
  3. SOCINSKI MA, Villaruz LC, Ross J
    Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression.
    Oncologist. 2016 Nov 7. pii: theoncologist.2016-0285.
    PubMed     Text format     Abstract available


  4. TOMASINI P, Walia P, Labbe C, Jao K, et al
    Targeting the KRAS Pathway in Non-Small Cell Lung Cancer.
    Oncologist. 2016 Nov 2. pii: theoncologist.2015-0084.
    PubMed     Text format     Abstract available


    October 2016
  5. LIU J, Wu L, Wu G, Hu X, et al
    A Phase I Study of the Safety and Pharmacokinetics of Higher-Dose Icotinib in Patients With Advanced Non-Small Cell Lung Cancer.
    Oncologist. 2016 Oct 27. pii: theoncologist.2016-0256.
    PubMed     Text format     Abstract available


    September 2016
  6. CHIAPPORI AA, Otterson GA, Dowlati A, Traynor AM, et al
    A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer.
    Oncologist. 2016 Sep 30. pii: theoncologist.2016-0220.
    PubMed     Text format     Abstract available


  7. WANG J, Zhou Z, Liang J, Feng Q, et al
    Intensity-Modulated Radiation Therapy May Improve Local-Regional Tumor Control for Locally Advanced Non-Small Cell Lung Cancer Compared With Three-Dimensional Conformal Radiation Therapy.
    Oncologist. 2016 Sep 14. pii: theoncologist.2016-0155.
    PubMed     Text format     Abstract available


    August 2016
  8. HERZBERG B, Campo MJ, Gainor JF
    Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
    Oncologist. 2016 Aug 17. pii: theoncologist.2016-0189.
    PubMed     Text format     Abstract available


  9. O'KANE GM, Labbe C, Doherty MK, Young K, et al
    Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer.
    Oncologist. 2016 Aug 17. pii: theoncologist.2016-0164.
    PubMed     Text format     Abstract available


    July 2016
  10. LEVY B, Hu ZI, Cordova KN, Close S, et al
    Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer.
    Oncologist. 2016 Jul 7. pii: theoncologist.2016-0082.
    PubMed     Text format     Abstract available


    June 2016
  11. CAMPO M, Al-Halabi H, Khandekar M, Shaw AT, et al
    Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer.
    Oncologist. 2016 Jun 27. pii: theoncologist.2015-0508.
    PubMed     Text format     Abstract available


  12. HORN L, Reck M, Spigel DR
    The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer.
    Oncologist. 2016 Jun 27. pii: theoncologist.2015-0523.
    PubMed     Text format     Abstract available


  13. KAZANDJIAN D, Blumenthal GM, Luo L, He K, et al
    Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer.
    Oncologist. 2016 Jun 21. pii: theoncologist.2016-0101.
    PubMed     Text format     Abstract available


  14. EATON KD, Jagels B, Martins RG
    Value-Based Care in Lung Cancer.
    Oncologist. 2016 Jun 2. pii: theoncologist.2016-0116.
    PubMed     Text format    


    May 2016
  15. DAGOGO-JACK I, Shaw AT
    Screening for ALK Rearrangements in Lung Cancer: Time for a New Generation of Diagnostics?
    Oncologist. 2016 May 31. pii: theoncologist.2016-0179.
    PubMed     Text format    


  16. ALI SM, Hensing T, Schrock AB, Allen J, et al
    Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
    Oncologist. 2016 May 31. pii: theoncologist.2015-0497.
    PubMed     Text format     Abstract available


  17. SUH JH, Johnson A, Albacker L, Wang K, et al
    Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.
    Oncologist. 2016 May 5. pii: theoncologist.2016-0030.
    PubMed     Text format     Abstract available


    April 2016
  18. CASTELLANOS EH, Horn L
    Re-Evaluating Progression in an Era of Progress: A Review of First- and Second-Line Treatment Options in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.
    Oncologist. 2016 Apr 6. pii: theoncologist.2015-0396.
    PubMed     Text format     Abstract available


  19. OLSZANSKI AJ, Smith DC, Camacho LH, Thompson J, et al
    Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors.
    Oncologist. 2016;21:402-3.
    PubMed     Text format     Abstract available


    March 2016
  20. SUL J, Blumenthal GM, Jiang X, He K, et al
    U.S. Food and Drug Administration Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
    Oncologist. 2016 Mar 29. pii: theoncologist.2015-0498.
    PubMed     Text format     Abstract available


  21. HEIST RS, Shim HS, Gingipally S, Mino-Kenudson M, et al
    MET Exon 14 Skipping in Non-Small Cell Lung Cancer.
    Oncologist. 2016 Mar 28. pii: theoncologist.2015-0510.
    PubMed     Text format     Abstract available


  22. KAZANDJIAN D, Suzman DL, Blumenthal G, Mushti S, et al
    FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
    Oncologist. 2016 Mar 16. pii: theoncologist.2015-0507.
    PubMed     Text format     Abstract available


  23. SIVA S, Ball D
    Curing Operable Stage I Non-Small Cell Lung Cancer With Stereotactic Ablative Body Radiotherapy: The Force Awakens.
    Oncologist. 2016 Mar 16. pii: theoncologist.2015-0477.
    PubMed     Text format    


  24. CIARDIELLO F, Adams R, Tabernero J, Seufferlein T, et al
    Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients.
    Oncologist. 2016;21:292-300.
    PubMed     Text format     Abstract available


    February 2016
  25. DE LA TORRE-VALLEJO M, Turcott J, Arrieta O, Baracos V, et al
    In Reply.
    Oncologist. 2016;21:e2.
    PubMed     Text format    


  26. CINTOSUN U, Altun B, Tasci I
    Sarcopenia Is a Condition With Increasing Importance in Medical Oncology.
    Oncologist. 2016;21:e1.
    PubMed     Text format    


  27. GOSS GD, Spaans JN
    Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung.
    Oncologist. 2016;21:205-13.
    PubMed     Text format     Abstract available


  28. SEKI Y, Fujiwara Y, Kohno T, Takai E, et al
    Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
    Oncologist. 2016;21:156-64.
    PubMed     Text format     Abstract available


    January 2016
  29. VERMA V, Simone CB 2nd, Zhen W
    Stereotactic Radiotherapy for Stage I Small Cell Lung Cancer.
    Oncologist. 2016 Jan 13. pii: theoncologist.2015-0348.
    PubMed     Text format    


  30. KUMAR P, Gareen IF, Lathan C, Sicks JD, et al
    Racial Differences in Tobacco Cessation and Treatment Usage After Lung Screening: An Examination of the National Lung Screening Trial.
    Oncologist. 2016;21:40-9.
    PubMed     Text format     Abstract available


    November 2015
  31. NIPP RD, Greer JA, El-Jawahri A, Traeger L, et al
    Age and Gender Moderate the Impact of Early Palliative Care in Metastatic Non-Small Cell Lung Cancer.
    Oncologist. 2015 Nov 30. pii: theoncologist.2015-0232.
    PubMed     Text format     Abstract available


  32. STENEHJEM DD, Bellows BK, Yager KM, Jones J, et al
    Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer.
    Oncologist. 2015 Nov 27. pii: theoncologist.2015-0162.
    PubMed     Text format     Abstract available


    October 2015
  33. LARKINS E, Scepura B, Blumenthal GM, Bloomquist E, et al
    U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy.
    Oncologist. 2015 Oct 7. pii: theoncologist.2015-0221.
    PubMed     Text format     Abstract available


    September 2015
  34. HEIGENER DF, Schumann C, Sebastian M, Sadjadian P, et al
    Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
    Oncologist. 2015 Sep 9. pii: theoncologist.2015-0073.
    PubMed     Text format     Abstract available


  35. LEVY BP, Chioda MD, Herndon D, Longshore JW, et al
    Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based Recommendations.
    Oncologist. 2015 Sep 1. pii: theoncologist.2015-0114.
    PubMed     Text format     Abstract available


    August 2015
  36. HALMOS B, Pennell NA, Fu P, Saad S, et al
    Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer.
    Oncologist. 2015 Aug 25. pii: theoncologist.2015-0136.
    PubMed     Text format     Abstract available


  37. LOURDES LS, Jalal SI, Hanna N
    Adjuvant Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer.
    Oncologist. 2015 Aug 12. pii: theoncologist.2015-0182.
    PubMed     Text format    


  38. PELED N
    In Reply.
    Oncologist. 2015;20:e25.
    PubMed     Text format    


    July 2015
  39. ARRIETA O, De la Torre-Vallejo M, Lopez-Macias D, Orta D, et al
    Nutritional Status, Body Surface, and Low Lean Body Mass/Body Mass Index Are Related to Dose Reduction and Severe Gastrointestinal Toxicity Induced by Afatinib in Patients With Non-Small Cell Lung Cancer.
    Oncologist. 2015 Jul 14. pii: theoncologist.2015-0058.
    PubMed     Text format     Abstract available


  40. SAXENA A, Becker D, Preeshagul I, Lee K, et al
    Therapeutic Effects of Repurposed Therapies in Non-Small Cell Lung Cancer: What Is Old Is New Again.
    Oncologist. 2015 Jul 8. pii: theoncologist.2015-0064.
    PubMed     Text format     Abstract available


  41. UGUEN A, Talagas M, Marcorelles P, Gueguen P, et al
    Next-Generation Sequencing and Immunohistochemistry as Future Gold Standard of ALK Testing in Lung Cancer?
    Oncologist. 2015 Jul 8. pii: theoncologist.2015-0123.
    PubMed     Text format    


  42. TAKAGI Y, Hosomi Y, Shibuya M, Okamoto H, et al
    In Reply.
    Oncologist. 2015;20:e22.
    PubMed     Text format    


    June 2015
  43. SINGH N, Maturu VN, Behera D
    Total Plasma Homocysteine Level Assessment and Timing of Folate/B12 Supplementation Prior to Initiation of Pemetrexed-Based Chemotherapy for Nonsquamous Non-Small Cell Lung Cancer Patients: An Irrelevant Investigation, an Unnecessary Delay, or Both?
    Oncologist. 2015 Jun 11. pii: theoncologist.2015-0040.
    PubMed     Text format    


    May 2015
  44. AHN MJ, Kim SW, Cho BC, Ahn JS, et al
    Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR.
    Oncologist. 2015;20:570.
    PubMed     Text format    


    March 2015
  45. SORIA JC, LoRusso P, Bahleda R, Lager J, et al
    Phase I dose-escalation study of pilaralisib (SAR245408, XL147), a pan-class I PI3K inhibitor, in combination with erlotinib in patients with solid tumors.
    Oncologist. 2015;20:245-6.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: